Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 0.49
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. In particular, the stock is 'expensive' on EV/EBITDA, ove
Data is available to registered users only
